image credit- shutterstock
The Saudi National Unified Procurement Company (NUPCO) has officially announced the bidding results for the three-year centralised procurement project for outsourced testing services for public hospitals. Genalive, the joint venture of BGI Genomics, secured the tender with a contract value of 950 million RMB.
BGI Genomics worked closely with Saudi Arabia during the global pandemic. It delivered comprehensive nucleic acid testing solutions and virus sequencing platforms. This partnership helped establish variant monitoring capabilities, strengthening the country’s public health infrastructure and making a significant impact on epidemic prevention and control.
The collaboration marks the largest outsourced testing service contract secured by Genalive in Saudi Arabia to date, will provide strong support for enhancing local precision medicine services.
This tender is the largest in NUPCO's history in terms of value and the number of testing items. It covers multiple methodologies, including NGS, pathology, cytogenetics, and Sanger sequencing. It includes 930,000 testing services and will provide comprehensive solutions for 83 public hospitals across Saudi Arabia.
Genalive will offer services in whole genome sequencing (WGS), whole exome sequencing (WES), monogenic disease panel, non-invasive prenatal testing (NIPT), hereditary cancer screening, and preimplantation genetic testing (PGT).
As a joint venture between BGI Genomics and Saudi partners, Genalive integrates China’s cutting-edge genomics technology with Saudi Arabia’s healthcare resources, offering a full-spectrum service model spanning diagnostics, equipment supply, and technical training.
